Methodology
How we evaluate evidence
Measured → Demonstrated → Uncertain
Three essential distinctions.
Measured
Optical and technical performance under defined test conditions.
Demonstrated
Clinical outcomes supported in the studied population.
Uncertain
Plausible, emerging or not yet established findings.
Calibrated conclusions.
Established
Supported by mature and reproducible evidence appropriate to the question.
Supported
Evidence supports the finding, while meaningful limitations remain.
Emerging
Early evidence is informative but not yet mature.
Not yet established
Plausible or claimed, but not adequately demonstrated by current evidence.
Editorial assessments of specific findings, not formal GRADE ratings, lens rankings or the six consensus-based functional IOL categories.
The question determines the evidence.
Design, methods, independence, endpoints and clinical relevance matter together. Evidence types are not a universal hierarchy.
Systematic reviews / meta-analyses
Synthesize consistency across studies. Interpretation depends on included designs, heterogeneity, overlap and the populations and endpoints pooled.
Randomized clinical trials
Can test a specified comparative clinical question. Masking, sample size, follow-up and prespecified endpoints determine what the result supports.
Prospective clinical studies
Describe planned patient outcomes over time. A single-arm study cannot isolate the advantage of one technology over another.
Observational / real-world evidence
Adds clinical context and practical experience. Selection, confounding, missing data and follow-up constrain causal interpretation.
Independent bench evidence
Can strongly inform optical mechanism under controlled conditions. Test conditions and model assumptions limit generalisation to patients.
Manufacturer bench / simulator evidence
Useful for specifications and design intent. Source, methods and access limitations remain explicit; simulated performance is not a patient outcome.
Registry data
Distinguish planned endpoints, recruitment and posted results. Registration is not a result; posted results are not equivalent to journal peer review.
Congress / early evidence
Can identify important emerging signals. Abstracts and presentations need full methods and results before conclusions can be weighed with the same confidence as complete publications.
Interpretation safeguards.
Bench ≠ clinical
An optical improvement requires clinical evidence before it becomes a demonstrated patient benefit.
Platform ≠ incremental benefit
Legacy evidence defines a baseline; a new generation needs its own evidence. Legacy and current-generation comparators remain distinct.
Not established ≠ no benefit
Insufficient evidence is not proof of absence. Statistical significance is assessed separately from clinical importance.
Trace the claim
Source type, population, endpoints, follow-up, limitations and evidence cutoff remain explicit. Narrative editorial reviews are not automatically systematic reviews.
Verified factual corrections are documented; substantive updates retain version history. Manufacturer and researcher corrections follow the same evidential standard.
One standard. Three publication families.
Market Analysis
Category-level clinical, technological and commercial dynamics.
Evidence Reviews
Evidence surrounding a defined technology or platform.
Frameworks
Independent scientific reference and interpretation models; their scope and limitations remain explicit.